



Syndax Pharmaceuticals, Inc.
 Investor Relations Department
 35 Gatehouse Drive
 Building D, Floor 3
 Waltham, MA 02451
 United States

[Visit IR website](#)

[Sign-up for Email alerts](#)

NASDAQ: SNDX

Last Trade:	9.07
Trade Time:	4:00 PM ET 02.23.18
Change:	-0.04 (-0.439%)
Day Range	8.63 - 9.24
52-Week Range	7.41 - 15.70
Volume	236,728


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Through our pipeline agents, entinostat, a late stage, class 1 specific HDAC inhibitor and SNDX-6352, a phase 1 anti-CSF-1R monoclonal antibody, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax corporate headquarters are in Waltham, MA.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- 02.22.18 [Syndax Announces Presentations at the 2018 American Association for Cancer Research Annual Meeting](#)
- 02.01.18 [Syndax Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca](#)
- 01.10.18 [Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer](#)
- 11.11.17 [Syndax Pharmaceuticals Announces Presentation of Data from Immuno-oncology Clinical Trials at the Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting](#)
- 11.07.17 [Syndax Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Clinical and Business Update](#)

Financial Information [\[View all \]](#)

- [Third Quarter Financial Results](#)
- 03.14.17 [Annual Report \(10-K\)](#)
- 04.07.17 [Proxy Statement \(DEF 14A\)](#)
- 11.08.17 [Quarterly Report \(10-Q\)](#)
- 08.10.17 [Quarterly Report \(10-Q\)](#)
- 05.09.17 [Quarterly Report \(10-Q\)](#)